0000727207 false 0000727207 2022-12-08 2022-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of report (Date of earliest event reported)                  December 8, 2022                                                                


Accelerate Diagnostics, Inc.

(Exact name of registrant as specified in charter)



(State or other jurisdiction of incorporation)


001-31822   84-1072256
(Commission File Number)   (IRS Employer Identification No.)


3950 South Country Club Road, Suite 470, Tucson, Arizona   85714
(Address of principal executive offices)   (Zip Code)


(520) 365-3100

(Registrant’s telephone number, including area code)


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol Name of each exchange on which
Common Stock, $0.001 par value per share AXDX

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On December 8, 2022, Ron Price notified Accelerate Diagnostics, Inc. (the “Company”) of his decision to retire as the Company’s Chief Commercial Officer, Americas. Mr. Price’s last day with the Company is expected to be on January 6, 2023. Mr. Price’s retirement is for personal reasons and is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.


In connection with Mr. Price’s resignation, on December 8, 2022, the Company and Mr. Price entered into a Separation Agreement and Release (the “Separation Agreement”), which provides that the Company will grant 104,338 restricted stock units to Mr. Price vesting on December 19, 2022 and subject to the terms and conditions of the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan. Pursuant to the Separation Agreement, Mr. Price has agreed to a general release of claims in favor of the Company, as well as certain restrictive covenants, including confidentiality, non-compete and non-solicitation provisions.


The foregoing description of the Separation Agreement is not complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed herewith as Exhibit 10.1 and incorporated herein by reference in its entirety.


Item 9.01 Financial Statements and Exhibits.


(d)           Exhibits.  


10.1   Separation Agreement and Release, dated December 8, 2022, by and between the Company and Ron Price
104   Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: December 13, 2022  
  /s/ Steve Reichling
  Steve Reichling
  Chief Financial Officer




Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Accelerate Diagnostics Charts.
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Accelerate Diagnostics Charts.